Clinical trials: Mixed Cancer
Leukemia, Lymphoma
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00547196
- Testing
- filgrastim, Busulfan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Brenner Tumor, Fallopian Tube Cancer
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
RATIONALE: Colony stimulating factors, such as sargramostim (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing and may also increase the number of immune cells found in bone marrow or…
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
- Trial name
- NCT00466960
- Testing
- sargramostim, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or…
- Conditions
- Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
- Trial name
- NCT02164461
- Testing
- Axalimogene filolisbac
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advaxis, Inc.
Mixed Gliomas
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
RATIONALE: Current therapies for adults with recurrent or refractory mixed gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the…
- Trial name
- NCT00003473
- Testing
- Atengenal, Astugenal
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Burzynski Research Institute
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
This phase I/II trial is studying the side effects and best dose of flavopiridol and to see how well it works in treating patients with lymphoma or multiple myeloma.
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma
- Trial name
- NCT00112723
- Testing
- alvocidib
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with v-myc myelocytomatosis viral oncogene homolog…
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT02213913
- Testing
- lenalidomide, etoposide, prednisone
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Chicago
Adult Fibrosarcoma, Adult Leiomyosarcoma
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
This phase II trial is studying how well AZD0530 works in treating patients with recurrent locally advanced, or metastatic soft tissue sarcoma.
- Conditions
- Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00659360
- Testing
- saracatinib
- Where
- 4 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
This phase III trial is studying how well combination chemotherapy works when given before radiation therapy and/or additional chemotherapy in treating young patients with newly diagnosed Hodgkin's lymphoma.
- Conditions
- Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma
- Trial name
- NCT00302003
- Testing
- radiation therapy, doxorubicin hydrochloride, vincristine sulfate
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Children's Oncology Group
Leukemia, Myeloid, Myelodysplastic Syndromes
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
The purpose of this study is to determine the maximum tolerated dose, dose limiting side effects, and the safety of increasing doses of lenalidomide in patients with AML and MDS who have a small amount of detectable disease after…
- Trial name
- UF-BMT-MRD-101 (NCT02370888)
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Florida
Malignant Melanoma
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
The purposes of this study are to describe the immune response to individual peptides after immunization with a combination of 8 peptides and CpG 7909 or Montanide ISA51; to determine the safety of the vaccines and; to document…
- Trial name
- NCT00145158
- Testing
- 8 HLA-A2-restricted peptides and Montanide ISA51, 8 HLA-A2-restricted peptides and CpG 7909
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Ludwig Institute for Cancer Research
Uterine Cancer
Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
The optimal sequence and /or modality for adjuvant therapy in the management of Mixed Mesodermal Tumors (MMT) clearly remains to be established.
- Trial name
- NCT00231842
- Testing
- Ifosfamide, Radiation Therapy, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Uterine Cancer, Endometrial Carcinoma
A Study of Nivolumab in Selected Uterine Cancer Patients
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer.
- Conditions
- Uterine Cancer, Endometrial Carcinoma, Carcinosarcoma, Leiomyosarcoma
- Trial name
- NCT03241745
- Testing
- Nivolumab
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow.
- Trial name
- NCT00238433
- Testing
- filgrastim, busulfan, melphalan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01678443
- Testing
- indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse
CT-011 MAb in DLBCL Patients Following ASCT
Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL) following relapse of the disease.
- Conditions
- Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT00532259
- Testing
- CT-011
- Where
- 27 sites in United States, India and 1 more
- Volunteers
- 72 people
- Sponsor
- CureTech Ltd
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
This pilot clinical trial studies cyclodextrin-based nanopharmaceutical CRLX101 in treating patients with advanced or metastatic stomach, gastroesophageal, or esophageal cancer that has progressed through at least one prior…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01612546
- Testing
- cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Central nervous system (CNS) malignancies are the second most common malignancy and the most common solid tumor of childhood, including adolescence.
- Conditions
- Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma
- Trial name
- NCT01884740
- Testing
- SIACI of Erbitux and Bevacizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Weill Medical College of Cornell University
Malignant Glioma
Study of Capecitabine to Treat Recurrent High Grade Gliomas
The purpose of this study is to determine if capecitabine is effective in the treatment of high grade gliomas that have returned after completing treatment.
- Trial name
- NCT00717197
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Advanced Cancers, Sarcoma
Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor
The goal of this clinical research study is to learn if heated intra-abdominal cisplatin can help to control abdominal tumors in patients having surgery to remove the tumors. The safety of this drug will also be studied.
- Trial name
- NCT01277744
- Testing
- Hyperthermic Peritoneal Perfusion (HIPEC), Cisplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme, Gliosarcoma
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
Background: Growth of new blood vessels (angiogenesis) provides many tumors, including brain tumors, with needed nutrients and oxygen for cancer cells to survive.
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00995007
- Testing
- ZD6474 (Vandetanib), Carboplatin
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Cancer Institute (NCI)